Summary
This blend combines BPC-157 and TB-500 (thymosin beta-4 or its fragment) in one vial, usually in equal amounts by mass. Both have been studied separately in tissue-repair models in animals. No published study has tested them together.
Components
How it works
The rationale offered by suppliers is complementary mechanisms: BPC-157 appears to act through VEGFR2 and nitric oxide signalling, while thymosin beta-4 regulates actin and cell migration. That is a hypothesis, not a demonstrated synergy.
Research use cases
Areas where BPC-157 + TB-500 blend has been studied. Inclusion here does not mean it works for that purpose.
- Combines the research areas of its components; see each component profile
What the research found
No combination studies
We found no published peer-reviewed study testing this exact combination in animals or people. Evidence comes only from studies of each component on its own.
Safety and open questions
Combining compounds can change how each behaves, and fixed ratios mean you cannot adjust one without the other. Component purity and identity are harder to verify in a blend, because a single certificate of analysis must confirm several peptides.
Regulatory status
Not approved. A supplier-defined combination; no regulator has evaluated it.
Status was accurate when this page was last reviewed on October 26, 2026. Regulations change; check with the relevant authority before relying on it.
BPC-157 + TB-500 blend: common questions
How do I calculate amounts for a blend?
All components dissolve into the same water, so every draw contains them in the same ratio as the vial. Use the blend calculator, which shows the amount of each component per draw.
Is BPC-157 + TB-500 blend approved for human use?
Not approved. A supplier-defined combination; no regulator has evaluated it.